Introduction
============

Karnataka, in southern India, has one of the highest prevalences of HIV among Indian states,[@b1] and is among the states included in the 'Avahan' India HIV/AIDS initiative established by the Bill & Melinda Gates Foundation in 2004. Working through state-level partners and local non-governmental organisations (NGOs), the initiative is a multifaceted HIV preventive intervention promoting prevention strategies among high-risk groups, including distribution of condoms to and promotion of condom use among female sex workers (FSWs).[@b2]

Assessing the impact of the Avahan intervention is crucial, not only to ensure that Avahan achieves its goals of reducing HIV transmission in India, but also to inform future large-scale interventions.[@b5] However, the dynamics of an HIV epidemic are complicated: declines in HIV prevalence can occur without any intervention effects, due to natural infection dynamics and, conversely, increases can occur even in the presence of an effective intervention.[@b6] [@b7] In order to separate out the impact of the Avahan initiative from natural HIV transmission dynamics, and because of the difficulty and huge expense of implementing community randomised controlled trials, a tailor-made transmission dynamics model will be used as one important component of the impact assessment, the framework for which is described in Boily *et al*.[@b8]

The final impact and cost effectiveness analysis, planned for 2011, will estimate the impact of the Avahan initiative on the HIV and sexually transmitted infection (STI) epidemics among high-risk groups and the broader population across more than 30 intervention sites.[@b5] [@b8] This paper presents the results of an interim analysis focusing on FSWs and their clients in two districts where sufficient data are currently available, and which represent different HIV/STI epidemic trends and behavioural profiles: Belgaum Urban, a higher prevalence district in which Avahan was not the first but is now the only intervention; and Mysore Urban, a lower prevalence district in which Avahan was the first and remains the only intervention.

The objective of this analysis is to determine whether the observed changes in HIV prevalence among FSWs could be solely due to natural disease dynamics rather than to a change in condom use following the intervention. We address this question by testing whether the null hypothesis (H~0~) of stable (ie, no increase in) condom use following the initiation of the Avahan intervention in 2004 is less likely than the alternative hypotheses (H~1~) that condom use actually increased by as much as reported in FSW survey data, or (H~2~) that there was a lower level of preintervention condom use and a sharper postintervention increase than indicated by FSW survey data, as suggested by records of condom availability.[@b9]

Methods
=======

In order to model the HIV/STI epidemics in urban Belgaum and Mysore districts, an in-depth mathematical modelling analysis was undertaken with the key elements described below.

Methodological framework of evaluation
--------------------------------------

The structure of the evaluation follows the methodological framework designed and described in Boily *et al*.[@b8] In short, a mathematical model was used within a Bayesian framework, where available data were first used to specify what was known about each model parameter by defining a plausible range of values (the 'prior distribution'). This distribution was then randomly sampled repeatedly, to test the model with a large number of parameter combinations and identify those parameter sets (the 'posterior distribution') that agreed with the empirical HIV/STI prevalence data shown in [table 1](#tbl1){ref-type="table"}.

###### 

HIV/sexually transmitted infection (STI) prevalence data from integrated behavioural and biological assessment (IBBA) surveys in Belgaum and Mysore used to fit (FSW IBBA rounds 1 and 2, and client IBBA round 1) and validate (FSW IBBA rounds 2 and 3) the model

  Survey                             District and date carried out   CI for prevalence                    
  ---------------------------------- ------------------------------- ------------------- ---------------- ----------------
  Fitting data                                                                                            
  FSW IBBA round 1                   Mysore (August 2004)            21.9% to 30.3%      59.6% to 69.1%   21.0% to 29.0%
  Belgaum (October 2005)             27.6% to 40.2%                  78.6% to 89.1%      3.0% to 13.0%    
  Client IBBA                                                                                             
  Round 1                            Mysore (October 2008)           3.2% to 7.6%        8.0% to 33.0%    1.3% to 4.6%
  Belgaum (October 2007)             3.6% to 8.8%                    23.3% to 32.3%      2.0% to 6.5%     
  Crossvalidation and fitting data                                                                        
  FSW IBBA round 2                   Mysore (December 2006)          19.1% to 29.5%                       
  Belgaum (July 2008)                22.2% to 32.5%                                                       
  Crossvalidation data                                                                                    
  FSW IBBA round 3                   Mysore (April 2009)             8.11% to 14.1%                       

FSW, female sex worker; HSV, herpes simplex virus.

One of the advantages of this approach is that the percentage of parameter sets producing a model fit to the prevalence data gives a measure of how compatible the prior parameter sets were with the observed prevalence data for the specified model. This approach was used here to test the three hypotheses described above concerning possible trends in condom use before and after the Avahan intervention. Finally, the posterior distribution was used to simulate a control group without the intervention, which was then compared to the original scenario to produce estimates of intervention impact.

Model structure and parameterisation
------------------------------------

A purpose-built deterministic compartmental model of HIV, herpes simplex virus (HSV)-2 and syphilis transmission was constructed and parameterised to incorporate key aspects and heterogeneities of the complex FSW and client structure specific to each setting.[@b10] In summary, the model consisted of an open population, growing at the rate described by census data,[@b11] stratified into 'high-risk' (FSWs and their clients) and 'low-risk' (the remaining population) groups. Based on work by Vickerman *et al*[@b4] , it was assumed in this model that there is no transmission between low-risk individuals. The high-risk groups (FSWs and their clients) were further stratified by variables showing strong associations with HIV prevalence and high-risk behaviour in analyses of data from serial cross-sectional surveys termed integrated behavioural and biological assessments (IBBAs).[@b10] [@b12]

The model simulates the transmission of HIV/STIs between FSWs and their clients through commercial and longer-term non-commercial partnerships, and the bridging infections from clients to low-risk women through their non-commercial partnerships, as shown in [figure 1](#fig1){ref-type="fig"}. The force of infection depends on the disease-specific infectivity, type and duration of partnership, frequency of sex acts for the type of partnership, condom use and STI coinfection status of both partners. The three parameters influencing HIV prevalence the most in a sensitivity analysis of a representative sample of the unrestricted model runs were the number of sex acts per partnership between FSWs and occasional clients, the male to female HIV transmission per sex act and the RR for increased transmissibility of primary HIV. Further details of the model and equations are provided in the supplementary material.

![Outline of the main aspects of sexual behaviour structure and population movements between risk groups that are included in the model. HIV/sexually transmitted infection (STI) transmission through main (plain arrow) and casual (dotted arrow) partnerships is shown. Female sex workers and clients engage in commercial sex for a time before returning to the general population and being replaced from the general population (thick arrow).](sti038950.f1){#fig1}

HIV was modelled with an initial short acute phase of high infectivity, followed by a long low-infectivity phase and a pre-AIDS phase of increased infectivity.[@b13] It was assumed that those with AIDS are chronically ill, and cease being sexually active. HSV-2 coinfection[@b14] and syphilis[@b15] were also modelled dynamically, with cofactors representing facilitation of HIV and HSV-2 acquisition and transmission.

The setting-specific behaviour-related, demographic-related and intervention-related prior model parameter distributions were derived from detailed serial cross-sectional behavioural and biological data (from IBBAs) collected from FSWs and their clients, and general population surveys (GPS) carried out as part of the Avahan monitoring programme, as well as from complementary data from other sources. The non-setting specific biological parameter ranges were based on reviews of relevant literature ([tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}). Prior distributions were assumed to be uniform across each parameter range; this was a 'conservative' choice to reflect the lack of precise knowledge and possibility of bias in the data used to estimate the parameters.

###### 

Prior biological model input parameters sampled at the fitting stage to obtain the posterior parameter sets for Mysore and Belgaum for the Avahan impact model (all durations are in months)

  Types of model input                                                         Definition of model input                                                                                                                                                                                                                                                                Model inputs                                                                                                                                                     Reference for model input value
  ---------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------
  Duration of infection stages                                                 Average duration of Ng/Ct:                                                                                                                                                                                                                                                               Reviewed in Korenromp *et al*.[@b16] Also depends on level of STI treatment.                                                                                     
  Males                                                                        2--5                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Females                                                                      2--12                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Female sex workers (FSWs)                                                    0.5--3                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Average duration of syphilis stages:                                         Available data was reviewed by Boily *et al* and Garnett *et al*[@b8] [@b15]                                                                                                                                                                                                                                                                                                                                                                              
  Primary (no treatment)                                                       1.51                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Secondary (no treatment)                                                     3--4.5                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Primary and secondary stage (with treatment)                                 1--5                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Latent phase (including treatment)                                           2--24                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Time between potential recurrences                                           6                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Immune/resistant phase                                                       12--60                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Average duration of HSV-2 stages:                                            From Cheong *et al*, Corey *et al*, Diamond *et al*, Koelle *et al*, Guinan *et al* and Benedetti *et al*.[@b17]Using Corey *et al*, Guinan *et al* and Wald *et al*.[@b18] [@b20] [@b23] [@b25]                                                                                                                                                                                                                                                          
  Primary stage                                                                0.36--0.66                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Symptomatic recurrence                                                       0.1--0.16                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Rate of HSV-2 symptomatic recurrences while:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  HIV negative                                                                 0.09--0.41                                                                                                                                                                                                                                                                               Corey *et al*, Diamond *et al*, Benedetti *et al*, Lafferty *et al* and Kim *et al*[@b18] [@b20] [@b21] [@b24] [@b28]                                            
  HIV positive                                                                 1--2×HIV negative rate                                                                                                                                                                                                                                                                   Using Schacker *et al* and Conant *et al*[@b31] [@b32]                                                                                                           
  Average duration of HIV stages:                                              Based on Grover and Shivraj, and Kumarasamy *et al*[@b33] [@b34]                                                                                                                                                                                                                                                                                                                                                                                          
  Initial HIV high viraemia phase                                              4--6                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Between initial high viraemia and pre-AIDS                                   70--90.5                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Pre-AIDS high viraemia phase                                                 6--18                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Transmission probabilities                                                   Probability of HIV transmission per sex act:                                                                                                                                                                                                                                             Reviewed in Holmes *et al*.[@b40] [@b67]                                                                                                                         
  Male to female:                                                              0.0006--0.0011                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Female to male                                                               0.0001--0.0014                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Sexual transmission multiplicative cofactor:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Initial high viraemia phase                                                  4.5--18.8                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Pre-AIDS high viraemia phase                                                 4.5--11.9                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Probability of Ng/Ct transmission per sex act                                0.05--0.2                                                                                                                                                                                                                                                                                Reviewed by Holmes *et al*, Hooper *et al*[@b40] [@b67]                                                                                                          
  Probability of syphilis transmission per sex act (male to female):           0.1--0.3                                                                                                                                                                                                                                                                                 Reviewed by Garnett *et al*[@b15]                                                                                                                                
  Ratio of transmission probabilities female to male:male to female            0.33--1.0                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Probability of HSV-2 transmission:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Latent/asymptomatic shedding stage (male to female)                          0.0005--0.002                                                                                                                                                                                                                                                                            Using Wald *et al* and Corey *et al*[@b37] [@b38]                                                                                                                
  RR male to female: female to male transmission                               2--5                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Primary stage                                                                2--6×6.7--25 times asymptomatic/latent transmission probability                                                                                                                                                                                                                          From Kim *et al*, Wald *et al* and Corey *et al*[@b30] [@b37] [@b38]                                                                                             
  Symptomatic recurrence stage                                                 1--3×6.7--25 times latent/asymptomatic transmission probability                                                                                                                                                                                                                          Wald *et al*, Kim *et al*, and Mertz *et al*[@b25] [@b30] [@b39]                                                                                                 
  Cofactors for HIV                                                            Average Ng/Ct cofactor per sex act for increasing susceptibility to HIV                                                                                                                                                                                                                  1.2--2.5                                                                                                                                                         Using Rottingen *et al*[@b13]
  Average syphilis cofactor per sex act for increasing susceptibility to HIV   2.1--3.3                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  HSV-2 cofactor per sex act for increasing HIV infectivity:                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Primary and symptomatic recurrence phases                                    1.27--2.57×1--2                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Asymptomatic/latent phase                                                    0.27--1.57×0.04--0.15×2--3                                                                                                                                                                                                                                                                                                                                                                                                                                
  HSV-2 cofactor per sex act for increasing HIV susceptibility:                Using Schacker *et al*, Nagot *et al*, Zuckerman *et al*, Baeten *et al*, Celum *et al*, Dunne *et al*, Delany *et al*, Mbopi-Keou *et al*, Augenbraun *et al*, LeGoff *et al* and Serwadda *et al*[@b31] [@b42] and Quinn *et al*[@b55] to convert from differences in HIV viral load                                                                                                                                                                    
  Asymptomatic/latent phase                                                    1--4.75                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Primary phase and symptomatic recurrence phase                               1.5--4.0 times asymptomatic cofactor                                                                                                                                                                                                                                                                                                                                                                                                                      
  Cofactors for HSV-2                                                          HIV cofactor per partnership for increasing HSV-2 infectivity:                                                                                                                                                                                                                           Using Celum *et al*, Corey *et al*, Freeman *et al* and Watson-Jones *et al*[@b45] [@b56] and converting to probability using Quinn *et al*[@b55]                
  Primary phase                                                                1--2.5                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Asymptomatic/latent phase                                                    2--4                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Symptomatic recurrence phase                                                 Same as primary                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Condom efficacies                                                            Condom efficacy per sex act for HIV                                                                                                                                                                                                                                                      80% to 95%                                                                                                                                                       Pinkerton *et al*[@b59] [@b60]
  Condom efficacy per sex act for HSV-2 and syphilis                           40% to 70%                                                                                                                                                                                                                                                                               Based on Wald *et al*, Oberle *et al*, Dobbins *et al*, Obasi *et al* and Huerta *et al*[@b37] [@b61]                                                            
  Condom efficacy per sex act for Ng/Ct                                        60% to 90%                                                                                                                                                                                                                                                                               Based on Holmes *et al*, Hooper *et al*, Austin *et al*, Barlow, Joesof *et al*, Sanchez *et al*, Gaydos *et al*, Niccolai *et al* and Zenilman *et al* [@b66]   

Ct, *Chlamydia trachomatis*; HSV, herpes simplex virus; *Neisseria gonorrhoeae*; STI, sexually transmitted infection.

###### 

Prior behavioural model input parameters sampled at the fitting stage to obtain the posterior parameter sets for Mysore and Belgaum for the Avahan impact model

  Types of model input                                                                                Definition of model input                                                               Mysore                                     Belgaum
  --------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ------------------------------------------ ---------------
  Demography                                                                                                                                                                                                                             
  Population size and demographic inputs                                                              Initial size of sexually active population                                              278000 (M)                                 268000 (M)
  268000 (F)                                                                                          257000(F)                                                                                                                          
  Fraction of female general population sexually active                                               75% to 95%                                                                              77% to 95%                                 
  Fraction of male general population sexually active                                                 Determined by available partnerships                                                    Determined by available partnerships       
  Average time spent sexually active                                                                  41.3 years (M)                                                                          41.5 years (M)                             
  42.4 years (F)                                                                                      42.2 years (F)                                                                                                                     
  Entry rate into sexually active population per year                                                 12000 (M)                                                                               12000 (M)                                  
  11000 (F)                                                                                           11000 (F)                                                                                                                          
  Migration of female sex workers (FSWs)                                                              Proportion of FSWs migrating                                                            0.3--0.44                                  0.05--0.20
  Multiplicative cofactor increasing prevalence of HIV among clients in sites to which FSWs migrate   1--2                                                                                    1--2                                       
  Sexual behaviour                                                                                                                                                                                                                       
  Long-term partnerships of FSWs and clients                                                          Percentage of clients currently married/cohabiting by duration:                                                                    
  0--1 years and 2--4 years                                                                           68%                                                                                     43% to 59%                                 
  5--9 years and 10+ years                                                                            68%                                                                                     83% to 93%                                 
  Percentage of FSWs currently married/cohabiting by duration:                                                                                                                                                                           
  0--1 years                                                                                          38.2% to 57.2%                                                                          9.8% to 40.3%                              
  2--4 years                                                                                          39.9% to 54.9%                                                                          11.6% to 39.9%                             
  5--9 years                                                                                          28.6% to 50.4%                                                                          21.5% to 48.6%                             
  10+ years                                                                                           23.1% to 46/7%                                                                          5.3% to 20.7%                              
  Percentage of FSWs currently married/cohabiting by typology:                                                                                                                                                                           
  Home based                                                                                          25.9% to 54.1%                                                                          11.4% to 29.7%                             
  Brothel based                                                                                       8.8% to 66.9%                                                                           13.1% to 28.9%                             
  Street based                                                                                        39.3% to 49.3%                                                                          9.0% to 43.9%                              
  Average frequency of sex acts with married/cohabiting partner for FSWs/clients (per month)          5.9--8.2 (clients)                                                                      9.5--11.7 (clients)                        
  5.9--8.2 (FSWs)                                                                                     5.6--9.5 (FSWs)                                                                                                                    
  Duration of long-term partnerships (cohabiting/married) if FSW, years                               8.6--13.0                                                                               16.6--21.7                                 
  Duration of long-term partnerships between clients and low-risk females, years                      20--30                                                                                  20--30                                     
  FSW sexual behaviour                                                                                Average weekly frequency of clients for:                                                                                           
  Home-based FSWs duration 0--1 years                                                                 2.5--5.1                                                                                5.5--26.1                                  
  Home-based FSWs duration 2--4 years                                                                 3.8--7.9                                                                                1.8--10.3                                  
  Home-based FSWs duration 5--9 years                                                                 2.8--8.2                                                                                5.7--10.0                                  
  Home-based FSWs duration 10+ years                                                                  4.6--14.6                                                                               7.0--11.0                                  
  Brothel-based FSWs duration 0--1 years                                                              15--25                                                                                  6.3--34.2                                  
  Brothel-based FSWs duration 2--4 years                                                              12--45                                                                                  13.5--26.2                                 
  Brothel-based FSWs duration 5--9 years                                                              4--15                                                                                   13.1--25.3                                 
  Brothel-based FSWs duration 10+ years                                                               5.2--16.6                                                                               8.9--17.9                                  
  Street-based FSWs duration 0--1 years                                                               6.5--9.2                                                                                4.8--13.6                                  
  Street-based FSWs duration 2--4 years                                                               7.5--9.4                                                                                1.1--13.0                                  
  Street-based FSWs duration 5--9 years                                                               7.2--9.8                                                                                2.4--10.2                                  
  Street-based FSWs duration 10+ years                                                                6.5--9.1                                                                                3.8--10.2                                  
  Number of sex acts with each client                                                                 1--3                                                                                    1--3                                       
  Average duration of sex work in months for:                                                                                                                                                                                            
  Home-based FSWs                                                                                     35--69                                                                                  160--224                                   
  Brothel-based FSWs                                                                                  49--189                                                                                 94--127                                    
  Street-based FSWs                                                                                   53--66                                                                                  138--251                                   
  Client sexual behaviour                                                                             Number of FSWs visited/month if:                                                                                                   
  Below median activity level                                                                         0.8--1.2                                                                                0.8--1.2                                   
  Above median activity level                                                                         2.9--3.8                                                                                2.32--2.78                                 
  Average duration of being client in months if below/above median activity level                     84--240/84--240                                                                         83--119/90--143                            
  Proportions of FSWs/clients by each stratification                                                  Percentage of female population who are FSWs                                            0.3% to 1.4%                               0.2% to 1.1%
  Percentage of male population who are clients                                                       Determined by number of FSW partnerships                                                Determined by number of FSW partnerships   
  Proportion of FSWs that are:                                                                                                                                                                                                           
  Home based                                                                                          0.08--0.15                                                                              0.23--0.50                                 
  Brothel based                                                                                       0.00--0.01                                                                              0.31--0.61                                 
  Street based                                                                                        0.85--0.91                                                                              0.11--0.24                                 
  Proportion of male clients who visit FSWs:                                                                                                                                                                                             
  Below median level (ie, low activity clients)                                                       0.5                                                                                     0.58--0.69                                 
  Above median level (ie, high activity clients)                                                      0.5                                                                                     0.31--0.42                                 
  Condom use                                                                                                                                                                                                                             
  Condom use in main partnerships                                                                     Average consistency of condom use between married/cohabiting partners per sex act.      4.3% to 10.3%                              5.2% to 12.7%
  Condom use between FSWs and clients                                                                 Fraction of sex acts with occasional clients for which a condom is used, by FSWs who:                                              
  Report 'always' using                                                                               0.81--0.93                                                                              0.81--0.93                                 
  Report often/sometimes using Report 'never' using                                                   0.54--0.67                                                                              0.54--0.67                                 
  0.07--0.38                                                                                          0.07--0.38                                                                                                                         
  Fraction of FSWs who are consistent condom users:                                                                                                                                                                                      
  At the start of the HIV epidemic in India                                                           0--0.1                                                                                  0--0.1                                     
  Under H~0~ and H~1~:                                                                                                                                                                                                                   
  At first time point                                                                                 0.111--0.228                                                                            0.286--0.422                               
  At second time point                                                                                0.233--0.395                                                                            0.759--0.855                               
  Under H~1~, at time of IBBA R2                                                                      0.615--0.729                                                                            0.855--0.926                               
  Under H~2~:                                                                                                                                                                                                                            
  At first time point                                                                                 0.1--0.220                                                                              0.1--0.220                                 
  At second time point                                                                                0.321--0.416                                                                            0.321--0.416                               
  At time of IBBA R2                                                                                  0.777--0.847                                                                            0.777--0.847                               
  Fraction of FSWs who report 'sometimes/often' using condoms with occasional clients at IBBA R2      0.245--0.367                                                                            0.074--0.145                               
  Dates                                                                                               Start of HIV epidemic in India                                                          1976--1985                                 1976--1985
  Under H~0~ and H~1~:                                                                                                                                                                                                                   
  At first time point                                                                                 2002                                                                                    2002                                       
  At second time point                                                                                2004                                                                                    2005                                       
  At time of IBBA R2                                                                                  2007                                                                                    2008                                       
  Under H~2~:                                                                                                                                                                                                                            
  At first time point                                                                                 2004                                                                                    2004                                       
  At second time point                                                                                2006                                                                                    2006                                       
  At time of IBBA R2                                                                                  2008                                                                                    2008                                       

FSW, female sex worker; H, hypothesis; IBBA, integrated behavioural and biological assessments; R, round.

The parameterisation of condom use before and after the intervention was data driven and specific to each hypothesis tested, resulting in three different prior condom use distributions. The prior distribution of condom use for hypothesis H~1~ was based on estimates (with CIs) of site-specific condom use from 2001 onwards given by the analysis of Lowndes *et al*.[@b75] That analysis used data from the IBBA round 2 surveys concerning time since starting to use condoms consistently with occasional clients to retrospectively 'reconstruct' the fraction of FSWs consistently using condoms each year from 2001 to the year of the survey. The null hypothesis H~0~ assumed the same increase in condom use prior to 2004 as hypothesis H~1~ but no further increase after the start of the Avahan intervention in 2004. A further hypothesis (H~2~) was based on HIV prevention programme data and other sources regarding the availability of condoms for FSWs[@b9] from 2004 to 2008 across Karnataka. This study suggested that the proportion of consistent condom users among FSWs in 2004 was much lower than suggested in hypothesis H~1~ due to low availability, but that it rose steeply during 2006--2008 due to the Avahan intervention. The three different condom prior distributions are shown in [figure 2](#fig2){ref-type="fig"}, with the round 1 and 2 FSW IBBA point estimates shown for comparison.

![Prior parameter ranges for hypotheses H~0~--H~2~ reflecting the proportion of female sex workers (FSWs) who are consistently using condoms for (a) Mysore and (b) Belgaum. The upper and lower lines show the range of the prior. Also shown is the data from the historic condom reconstruction, and mean and 95% CIs for the FSW integrated behavioural and biological assessment (IBBA) values.](sti038950.f2){#fig2}

Parametric uncertainty analysis, model fitting and validation
-------------------------------------------------------------

This step involved identifying combinations of model parameters that agreed with ('fit') the HIV/STI prevalence data from each site for each condom use hypothesis tested. Latin hypercube sampling (LHS) was used to sample several million parameter sets from all 'prior' parameter ranges for each hypothesis and district, with the sampling done so that the same set of parameters, excluding the intervention parameters being tested, were used for the different hypotheses in each district. The model was run with each sampled parameter set to predict HIV/STI prevalences. A parameter set was accepted as a fit if the model predictions simultaneously lay within the 95% CIs of the HIV, HSV-2 and syphilis prevalence data of the relevant FSW and client IBBAs, as described below.

The HIV/STI prevalence data from FSWs and clients for each district were used in two stages: (1) as validation and (2) for hypothesis testing. In stage 1, the model was first fitted to just the round 1 FSW and client IBBA HIV, HSV-2 and syphilis prevalence data (see [table 1](#tbl1){ref-type="table"}), and the predictive value of these model fits was assessed against the HIV prevalence data not used directly at this stage of the fitting process, namely FSW HIV prevalence from the second round FSW IBBA in Mysore and Belgaum ([table 1](#tbl1){ref-type="table"}) and third round in Mysore ([table 1](#tbl1){ref-type="table"}), and FSW HIV prevalence by typology (street, brothel or home based) in rounds 1 and 2 (see supplementary material). In stage 2, the second round of IBBA HIV prevalence data were included in the fitting procedure along with the first round of FSW and client IBBA HIV/STI prevalence data ([table 1](#tbl1){ref-type="table"}) to produce a reduced set of model fits for hypothesis testing.

Testing hypotheses of condom use
--------------------------------

The most likely condom use hypothesis was determined based on the relative proportions of fits to the first round FSW and client IBBA HIV/STI prevalence data and the second round FSW HIV prevalence data. For each hypothesis, the fraction of model fits from all parameter sets was compared to determine which hypothesis was more likely. This method, which is related to the version of Approximate Bayesian Computing as described by Weiss and von Haeseler,[@b76] is also similar to the Bayesian methods used by Vickerman *et al* for determining the likelihood of different injecting drug user risk behaviour scenarios in Pakistan,[@b77] and Hallett *et al* for examining behaviour change in Zimbabwe.[@b78]

Impact analysis
---------------

The posterior distribution of the most likely condom use hypothesis was used to simulate HIV prevalence and incidence over time following the start of the intervention, and in a matched control population. In the latter, each model fit was run again with condom use kept constant at 2004 levels (ie, at the start of the Avahan initiative). Comparing the impact and control scenarios, estimates of the impact of the increase in condom use following the start of the intervention among high-risk groups were derived for a 5-year period (2004--2009). These estimates derived from the posterior distribution include credibility intervals (CrI) generated by using all the parameter combinations that fit the prevalence data to reflect the uncertainty in parameter assumptions, since more than one set of parameters may produce an equally good fit to epidemiological trends.

Results
=======

Hypothesis testing
------------------

The proportion of fits to each hypothesis is shown in [table 4](#tbl4){ref-type="table"}. In Mysore, the hypothesis H~2~, derived from analysing availability of condoms, gives the largest proportion of simulations which are consistent with prevalence data, and scenarios H~2~ and H~1~ of increasing condom use following the introduction of Avahan are more likely than the null hypothesis H~0~ of no condom increase after the start of Avahan, for which no model fits were obtained. In Belgaum, however, the null hypothesis H~0~ of no increase use in condom use following Avahan and the alternative hypothesis H~1~, based on the historical condom use reconstruction, cannot be distinguished by this method, although both are much more likely than the hypothesis H~2~. An alternative method to comparing the proportion of fits would be a likelihood-based approach, calculating the likelihood for each run; however this method gave comparable results (data not shown).

###### 

Number of fits per million runs for each hypothesis (H) (fits to round (R)1 data only are shown for comparison to validate time trends of the model in HIV prevalence)

                                       Mysore   Belgaum                                
  ------------------------------------ -------- --------- ---------- ------ ---------- -------
  Fits to R1 FSW and client IBBAs      0        48.3      86         11.3   9.7        0
  Fits to R1+R2 FSW and client IBBAs   0        36 (S)    82.7 (S)   9.7    8.3 (NS)   0 (S)

FSW, female sex worker; IBBA, integrated behavioural and biological assessments; NS, not statistically different to H~0~ at the 5% level using χ^2^ test; S, statistically significantly different to H~0~.

Crossvalidation of results
--------------------------

[Table 4](#tbl4){ref-type="table"} shows that fits to only the round 1 FSW and client IBBA prevalence data ([table 4](#tbl4){ref-type="table"}) also generally fit the round 2 FSW IBBA HIV prevalence data well for all hypotheses (90% or more of posterior runs also fit FSW HIV round 2 prevalence). This then validates the model with respect to time trends in HIV (see also supplementary material). A third round of IBBA data was available for Mysore only, and the model HIV prevalence projections were slightly higher (12.1% to 20.6% for H~2~; 12.4% to 19.6% for H~1~) than the third round IBBA data (8.1% to 14.1%). This is consistent with the fact that any further increases subsequent to the IBBA round 2 in condom use were not incorporated in the model.

Lastly, validation of the model by comparing its projections with FSW HIV prevalence by typology generally showed good agreement, although there was some residual heterogeneity, as might be expected (see supplementary material).

Trends in HIV/STI prevalence and incidence
------------------------------------------

The predicted prevalences over time for the model fits from the favoured hypotheses (H~0~ and H~1~ for Belgaum and H~2~ for Mysore) suggest that the HIV epidemics among FSWs and clients are declining in both districts ([figure 3A--F](#fig3){ref-type="fig"}). In Belgaum, it is likely that this decline began before Avahan started, around the year 2000, while in Mysore the decline probably started shortly after Avahan, in 2004--2005. Modelled incidence and the prevalence for hypothesis H~1~ for Mysore show similar trends (see supplementary material). More details of the general characteristics of the model runs and fits are included in the supplementary material.

![HIV prevalence over time for most likely hypothesis for (a) female sex workers (FSWs) and (b) clients in Mysore (H~2~); (c) FSWs and (d) clients in Belgaum (H~0~); and (e) FSWs and (f) clients in Belgaum (H~1~). Shown on the graphs are median, 25th and 75th percentiles, and the 95% credibility interval (lighter shaded area). For H~1~ Belgaum and H~2~ Mysore the prevalence of the simulated control groups is also shown (median, 25th and 75th percentiles, and 95% credibility interval). Also shown is the integrated behavioural and biological assessment (IBBA) prevalence data.](sti038950.f3){#fig3}

In Mysore, the median relative decline in HIV prevalence in 2009 compared to 2004 ('time decline') under H~2~ was 36.2% (95% CI 21% to 51%) in FSWs (median 25.6%, 95% CI 7% to 42% in clients), whereas the median relative decline in 2009 prevalence compared to a simulated scenario without any increase in condom use since 2004 ('intervention decline') was 44.7% (95% CI 35% to 52%) in FSWs (37.9%, 95% CI 30% to 45% in clients). In Belgaum, under H~1~, the median time decline was 47.6% (95% CI 39% to 58%) in FSWs (median 55.7%, 95% CI 48% to 66% in clients) while the median intervention decline was actually lower at 23.1% (95% CI 17% to 30%) in FSWs (28.4%, 95% CI 22% to 36% in clients). Thus, the time decline in HIV prevalence slightly underestimates the intervention decline in Mysore for hypothesis H~2~ and overestimates it in Belgaum for hypothesis H~1~.

Intervention impact among high-risk groups
------------------------------------------

We estimated the impact of the increase in condom use following the start of Avahan using the most likely hypothesis as the simulated intervention group/population, and using the null hypothesis H~0~ as the simulated matched control group/population. In Mysore, the increase in condom use between 2004 and 2009 may have prevented 31.3% to 47.4% of new HIV infections in FSWs and 32.7% to 47.2% in clients under hypothesis H~2~ ([figure 4](#fig4){ref-type="fig"} shows this in comparison to the impact projections for hypothesis H~1~). Impact increases over time, with 58.7% to 82.2% of new HIV infections prevented among FSWs in 2008 and 64.1% to 85.1% among clients under hypothesis H~2~ (41.2% to 72.2% and 47.1% to 77.6% under H~1~).

![Fraction of new HIV infections averted over a 5-year period from 2004 in female sex workers (FSWs) and clients as a result of increases in condom use for (A) Mysore under hypotheses H~1~ and H~2~ and (B) Belgaum under hypotheses H~1~. Shown on the graph are the median (middle line in the box), 25th and 75th percentiles (box) and the 95% credibility interval (whiskers). Belgaum hypothesis H~0~ corresponds to no impact, and is not shown.](sti038950.f4){#fig4}

In Belgaum, hypothesis H~0~, where condom use remains constant from 2004 onwards, suggests no impact. In comparison, the H~1~ scenario projects that 24.8% to 43.2% of new FSW HIV infections and 30.9% to 53.1% of new client infections were prevented in Belgaum by the increase in condom use between 2004 and 2009 ([figure 4](#fig4){ref-type="fig"}). As for Mysore, impact increases over time in the H~1~ scenario, with 32.7% to 59.7% of new infections in FSWs and 42.0% to 72.6% in clients prevented in 2008.

Discussion
==========

With sufficient data to inform model parameters and validate model predictions, the use of mathematical models within a Bayesian framework enables the testing of hypotheses about the value or range of more uncertain parameters,[@b77] [@b78] such as the evolution of condom use over time. In this analysis we have tested whether condom use is likely to have increased following the implementation of the Avahan intervention. In theory this could have been done more directly if unbiased baseline data on condom use had been collected; however, in practice it was not possible because such data could only be collected once the intervention was sufficiently well established to map and sample FSWs.

The success rates obtained in the hypothesis-testing analysis support the conclusion that in Mysore condom use during commercial sex increased substantially after the beginning of the intervention. This increase most likely occurred shortly after the beginning of the intervention, as suggested by data on availability of condoms. Although there was no significant decrease in the FSW IBBA prevalence data between rounds 1 and 2, the model suggests that, in the absence of an increase in condom use after 2004, prevalence would have increased, and so to obtain the required trend a significant increase in condom use was required. In Belgaum, the model results show that decreases in prevalence alone from the IBBA surveys are insufficient to distinguish between the hypotheses of increased condom use as reported by FSWs and constant condom use following the beginning of the intervention. Without information from other sources, it is not possible to definitely conclude that there has been an increase in condom use in commercial sex in Belgaum. The results also suggest that the level of condom use was higher in Belgaum than in Mysore prior to 2004. In Belgaum, a smaller-scale intervention was present for some years prior to 2004,[@b79] before it was scaled up by Avahan. Condom use by FSWs with clients may therefore have been higher at the start of the intervention than in Mysore, where there was no prior intervention.

The model results indicate that HIV incidence and prevalence have declined over time. The decline occurred earlier in Belgaum than in Mysore because condom use became widespread earlier, but perhaps also because the epidemic matured earlier. In Mysore, the decline roughly coincides with the beginning of the intervention. This pattern of decrease in prevalence agrees with that seen by Vickerman *et al*,[@b4] and by Boily *et al*[@b80] examining ANC data. While this study only considers high-risk individuals, the decline observed among FSWs and clients should translate to a slower decline in the general population in both districts, as shown in the analysis by Vickerman *et al*.[@b4]

The relative decline in HIV prevalence in Mysore in 2009 compared to the simulated control group ('intervention decline') is higher than the decline over time since 2004 ('time decline'). This is because the epidemic was still growing in 2004. In Belgaum, under the hypothesis of increasing condom use after Avahan, the intervention decline is smaller than the time decline, as the epidemic there was already declining prior to Avahan. This highlights that time trends alone should not be used to evaluate an intervention, and that modelling results are important to complement prevalence data in carrying out an evaluation.[@b6] [@b8] [@b80]

Strengths and limitations
-------------------------

The model described in this paper was specifically tailored to reflect the behavioural and biological heterogeneities present in these settings, with dynamical modelling of HSV-2 and syphilis in addition to HIV in each site. It was parameterised using data from multiple surveys among FSWs, clients and general population, and captured key epidemiological trends in HIV, HSV-2 and syphilis by risk groups. This model also compared well to an independent model by Vickerman *et al*,[@b4] and it was also validated with respect to time trends in HIV and FSW HIV prevalences by typology.

The framework described in Boily *et al*[@b8] was used to produce point estimates and credibility intervals of intervention impact by the creation of control groups that assumed no increase in condom use. This control group gives the impact due to the increase in condom use since the beginning of the intervention, and, in situations where condom use would have increased naturally even without an intervention to drive it, will overestimate intervention impact. Conversely, in the absence of a likely increase in condom use following Avahan, as may have been the case in Belgaum, this choice of control group results in the model projecting no HIV infections averted, while it is possible that there would still have been a decline in condom use in this situation without an intervention to sustain it. Indeed, analysis of a slow, modest decrease in consistent condom use of 10% over 5 years suggests that even such a small decline in condom use leads to a large impact (17.3% to 29.7% additional new FSW HIV infections between 2004--2009 due to the decrease in condom use), and thus the contribution of the intervention in sustaining condom use is important, although it is difficult to attribute directly.

The precision of the estimates was limited by data availability. In both districts, the fitting success rate was modest because conservative (wide) prior ranges were used for most parameters to capture their uncertainty, and because the model had to fit seven separate prevalence outcomes. If more data were available, then it would be possible to use this additional information to reduce the width of these priors and so possibly identify a higher proportion of model fits. This would allow a stronger comparison between the condom use scenarios, and would better reflect uncertainty in the impact projections. HIV prevalence data for earlier in the epidemic would also enable us to better constrain the trajectory of the early epidemic and so rule out unlikely epidemics with high early prevalence. However, using a constraint such as FSW prevalence being \<10% in 1985 did not change the impact estimates significantly (data not shown).

The picture is further complicated in Belgaum because the first IBBA survey was carried out 16 months after the start of the Avahan initiative, and so behavioural and epidemiological data reflected a situation in which Avahan was already present and where consistent condom use rates reported by FSW in the 2005 IBBA were already very high, at 91%. In contrast, the survey in Mysore is likely to be more comparable to the pre-Avahan baseline as it took place 8 months after the start of Avahan. It is difficult to quantify the impact of a change in behaviour in situations where there was a pre-existing intervention and a long delay between the start of the intervention and the first IBBA survey, such as in Belgaum. Impact estimation is more uncertain in such settings because it is hard to define and simulate a control group reflecting how condom use would have decreased without the intervention, for which no data are available. An additional round of behavioural and HIV prevalence data for FSWs in Belgaum could help to further inform impact estimates by giving extra information about how the epidemic there is changing.

In Belgaum, the low number of fits from the model to the prevalence data may be largely explained by the difficulty of fitting the relatively high HIV prevalence in clients. This analysis modelled the transmission of HIV/STIs among urban clients, since the IBBA was carried out in urban areas where the intervention started. However the size of the FSW population is higher in rural areas, and as city clients may also go to smaller towns and villages to visit FSWs, the urban client HIV prevalence may be influenced by the large rural FSW population. Future data collection strategies for programme evaluation should be adapted to reflect the reality of how the epidemic is driven and the nature of the intervention.

Conclusions
-----------

Dynamical modelling, used within a Bayesian framework, is useful for testing hypotheses and providing informative and less subjective impact estimates on which to base decisions. This method of comparing proportions of fits of different scenarios is relatively straightforward to implement, as shown here and in another recent analysis,[@b77] and helps to further augment survey findings of behaviours that are prone to reporting biases, such as condom use.

This analysis suggests that the HIV epidemics in Belgaum and Mysore are declining. In Belgaum, it is probable that the decline in HIV prevalence started before the beginning of the Avahan intervention, since condom use by FSWs with their clients was already high in this district due to pre-existing interventions. The model, using current prevalence data alone, is unable to distinguish between scenarios where condom use in commercial sex was sustained at existing levels and where it increased after Avahan. If there was a rise in condom use, as suggested by other data[@b9] and equally likely compared to the null hypothesis from this method, this increase would have averted 24.8% to 43.2% of HIV infections in FSWs and 30.9% to 53.1% of infections in clients between 2004 and 2009. If, however, Avahan only sustained the existing level of condom use attained by FSWs prior to Avahan, this is still important for controlling the epidemic, as even a small, gradual decline in condom use can greatly increase the number of new infections. This conclusion on impact, of including both scenarios, is conservative (which is deemed preferable), since the difference in proportion of fits between the hypotheses where condom use does or does not increase after 2004 is small. However, combined with the additional data presented in Bradley *et al*[@b9] regarding the availability of condoms in Belgaum, it can be argued that it is likely that there has been an increase in condom use since the start of Avahan.

In Mysore, the findings strongly suggest that condom use during commercial sex has increased since the introduction of the Avahan programme, and that this increase in condom use has averted 31.3% to 47.4% of HIV infections in FSWs and 32.7% to 47.2% in clients in Mysore over the first 5 years.

###### Key messages

-   Transmission dynamics models used within a Bayesian framework are useful tools to help evaluate large-scale intervention in absence of a control group. Such a framework enables testing of different hypotheses and provides credibility intervals for estimates of infections averted.

-   Our modelling analysis suggests there has been a decrease in HIV prevalence in high-risk groups due to an increase in condom use since the beginning of the Avahan intervention in Mysore.

-   Due to data limitations, our analysis could not say conclusively whether the change in prevalence in Belgaum was due to an increase in condom use following the start of the intervention, or simply the result of the natural dynamics and increase in condom use before 2004.
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